deltatrials
Completed INTERVENTIONAL NCT03598790

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE BRIGHT)

A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Sponsor: UCB Biopharma SRL

Conditions Chronic Plaque Psoriasis Moderate to Severe Chronic Plaque Psoriasis
Interventions Bimekizumab
Updated 44 times since 2018 Last updated: Apr 2, 2026 Started: Sep 5, 2018 Primary completion: Nov 14, 2023 Completion: Nov 14, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03598790, this observational or N/A phase trial focuses on Chronic Plaque Psoriasis and Moderate to Severe Chronic Plaque Psoriasis and remains completed. Sponsored by UCB Biopharma SRL, it has been updated 44 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Study Description(click to expand)

The study consists of a 144-week Treatment Period (open-label) and an optional 48-week Open-Label Extension Period 2 (OLE2) for eligible subjects in the USA and Canada.

The study consists of a 144-week Treatment Period (open-label) and an optional 48-week Open-Label Extension Period 2 (OLE2) for eligible subjects in the USA and Canada.

Status Flow

~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Oct 2019 · 6 months · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~Jul 2020 · 6 months · monthly snapshot~Jul 2020 – ~Nov 2020 · 4 months · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Aug 2023 · 2 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Jan 2026 · 3 months · monthly snapshot~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshot~Feb 2026 – ~Apr 2026 · 2 months · monthly snapshotApr 16, 2026 – present · 3 months · daily API

Change History

44 versions recorded

  1. Apr 16, 2026 — Present [daily]

    Completed

    Phase: PHASE3 → None

  2. Feb 2026 — Apr 2026 [monthly]

    Completed PHASE3

  3. Jan 2026 — Feb 2026 [monthly]

    Completed PHASE3

  4. Oct 2025 — Jan 2026 [monthly]

    Completed PHASE3

  5. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE3

▶ Show 39 earlier versions

  1. Feb 2025 — Sep 2025 [monthly]

    Completed PHASE3

  2. Jan 2025 — Feb 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Jan 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Jan 2024 — Jul 2024 [monthly]

    Completed PHASE3

  6. Dec 2023 — Jan 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  7. Nov 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE3

  8. Oct 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE3

  9. Sep 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE3

  10. Aug 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE3

  11. Jun 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE3

  12. May 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE3

  13. Apr 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE3

  14. Mar 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE3

  15. Feb 2023 — Mar 2023 [monthly]

    Active Not Recruiting PHASE3

  16. Jan 2023 — Feb 2023 [monthly]

    Active Not Recruiting PHASE3

  17. Dec 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE3

  18. Nov 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE3

  19. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE3

  20. May 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  21. Mar 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE3

  22. Jan 2022 — Mar 2022 [monthly]

    Active Not Recruiting PHASE3

  23. Sep 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE3

  24. Mar 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

  25. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE3

  26. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  27. Nov 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE3

  28. Jul 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  29. Jan 2020 — Jul 2020 [monthly]

    Recruiting PHASE3

  30. Nov 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  31. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

  32. Apr 2019 — Oct 2019 [monthly]

    Recruiting PHASE3

  33. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE3

  34. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE3

  35. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE3

  36. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  37. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

  38. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  39. Aug 2018 — Oct 2018 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

This is a study to evaluate the long-term safety and tolerability of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).

Contact Information

Sponsor contact:
  • UCB Biopharma SRL
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ajax, Canada , Alpharetta, United States , Asahikawa, Japan , Bakersfield, United States , Baton Rouge, United States , Berlin, Germany , Beverly, United States , Bialystok, Poland , Bialystok, Poland , Bialystok, Poland and 179 more locations